Matrix Asset Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,929
Closed -$212K 106
2025
Q4
$212K Buy
+3,929
New +$189K 0.02% 103
2025
Q3
Sell
-4,729
Closed -$219K 108
2025
Q2
$219K Buy
4,729
+637
+16% +$31.3K 0.02% 103
2025
Q1
$250K Sell
4,092
-1,357
-25% -$79.1K 0.03% 94
2024
Q4
$308K Sell
5,449
-170
-3% -$9.5K 0.03% 87
2024
Q3
$291K Buy
5,619
+15
+0.3% +$704 0.03% 82
2024
Q2
$233K Buy
5,604
+55
+1% +$2.46K 0.03% 93
2024
Q1
$301K Buy
5,549
+109
+2% +$5.55K 0.04% 76
2023
Q4
$279K Hold
5,440
0.04% 82
2023
Q3
$316K Hold
5,440
0.05% 73
2023
Q2
$348K Sell
5,440
-20
-0.4% -$1.34K 0.05% 76
2023
Q1
$378K Sell
5,460
-1,190
-18% -$83.9K 0.05% 70
2022
Q4
$478K Hold
6,650
0.07% 68
2022
Q3
$473K Sell
6,650
-35
-0.5% -$2.54K 0.08% 62
2022
Q2
$515K Sell
6,685
-499
-7% -$38K 0.08% 61
2022
Q1
$525K Sell
7,184
-997
-12% -$66.9K 0.07% 64
2021
Q4
$510K Sell
8,181
-9
-0.1% -$528 0.07% 65
2021
Q3
$485K Buy
8,190
+6
+0.1% +$395 0.07% 62
2021
Q2
$547K Buy
8,184
+22
+0.3% +$1.44K 0.08% 58
2021
Q1
$515K Sell
8,162
-2,497
-23% -$155K 0.08% 66
2020
Q4
$661K Buy
10,659
+15
+0.1% +$922 0.11% 60
2020
Q3
$642K Buy
10,644
+10
+0.1% +$602 0.12% 57
2020
Q2
$625K Sell
10,634
-2
-0% -$120 0.12% 53
2020
Q1
$593K Sell
10,636
-1,064
-9% -$65K 0.14% 51
2019
Q4
$751K Sell
11,700
-605
-5% -$34.6K 0.12% 52
2019
Q3
$624K Hold
12,305
0.11% 51
2019
Q2
$558K Buy
12,305
+5
+0% +$233 0.1% 54
2019
Q1
$587K Sell
12,300
-2,934
-19% -$146K 0.1% 52
2018
Q4
$792K Sell
15,234
-2,005
-12% -$108K 0.15% 50
2018
Q3
$1.07M Hold
17,239
0.17% 49
2018
Q2
$954K Sell
17,239
-695
-4% -$37.5K 0.16% 50
2018
Q1
$1.13M Sell
17,934
-30
-0.2% -$1.93K 0.19% 50
2017
Q4
$1.1M Sell
17,964
-10
-0.1% -$625 0.17% 49
2017
Q3
$1.15M Buy
+17,974
New +$1.05M 0.19% 49

Other funds holding BMY

Matrix Asset Advisors's BMY Position: Q1 2026 in Review

Matrix Asset Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 3,929 shares — an estimated $212K sold.

Matrix Asset Advisors first reported a position in BMY in Q3 2017 and held it in 33 quarters. The position peaked at $1.15M in Q3 2017. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Matrix Asset Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • Matrix Asset Advisors sold 3,929 Bristol-Myers Squibb shares in Q1 2026, an estimated $212K.
  • Matrix Asset Advisors first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 33 quarters.
  • Matrix Asset Advisors's Bristol-Myers Squibb position peaked at $1.15M in Q3 2017.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Matrix Asset Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.